Georgia's Online Cancer Information Center

Find A Treatment Site

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

Nancy N. and J.C. Lewis Cancer & Research Pavilion (LCRP) at St. Joseph's/Candler
NCI Community Cancer Centers Program (NCCCP)
Savannah, Georgia

The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) is a network of hospital cancer centers that serve as a community-based platform to support basic, clinical, and population-based research initiatives across the cancer care continuum—from prevention, screening, diagnosis, treatment, and survivorship through end-of-life care. One of the goals of the NCCCP is to increase access to clinical trials in a community setting. Through a strategic partnership between the NCI and participating hospitals, the NCCCP is a hospital-based cancer center network designed to support cancer research, and enhance access to and increase quality of care at community hospitals so more patients benefit from the latest research.

The Nancy N. and J.C. Lewis Cancer & Research Pavilion (LCRP) was one of the first of ten health systems selected by the NCCCP in 2007 to participate in what was originally a pilot program. It has since grown to a full-fledged program with 30 locations. As a National Cancer Institute NCCCP site, clinical research is one of the top goals of the LCRP. Every month the LCRP initiates several new clinical trials and anticipates having trials to offer patients with virtually every type and stage of cancer. Scientific breakthroughs lead to positive changes in the fight against cancer, and these trials will assist the LCRP in its dedication to deliver the best level of patient care in their own community.

www.sjchs.org
www.cancerpavilion.com

Treatment Sites in Georgia

Clinical Trials in Georgia

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type: Unknown Primary

A Four Arm Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib / Olaparib and the Combination of Olaparib / Wee1 Inhibitor AZD1775 in Women with Recurrent, Persistent or Metastatic Endometrial Cancer (EEC)
Cancer Type: Endometrial Cancer

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Cancer Type: Lung Cancer

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer among BRCA1 Carriers [SOROCk]
Cancer Type: Unspecified

A Phase II / III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
Cancer Type: Head and Neck Cancer

A Phase II Randomized Study of Adjuvant versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Cancer Type: Melanoma, Skin Cancer (Non-Melanoma)

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Cancer Type: Breast Cancer

A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Cancer Type: Unspecified

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Cancer Type: Unspecified

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Cancer Type: Skin Cancer (Non-Melanoma)

A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors
Cancer Type: Unspecified

A Phase III Randomized Trial of Radiation + / - MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Cancer Type: Unspecified

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Cancer Type: Unspecified

A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Cancer Type: Unspecified

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Cancer Type: Unspecified

A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer
Cancer Type: Colon/Rectal Cancer, Skin Cancer (Non-Melanoma)

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced / Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
Cancer Type: Colon/Rectal Cancer

A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
Cancer Type: Unspecified

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Cancer Type: Cervical Cancer, Gynecologic Cancers

A Randomized Phase III Study of Ibrutinib plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (> / = 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Cancer Type: Leukemia

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Cancer Type: Breast Cancer

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Cancer Type: Melanoma, Unknown Primary

A Randomized Phase III Trial of Induction / Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
Cancer Type: Unspecified

A Randomized Phase III, Two-Arm Trial of Paclitaxel / Carboplatin / Maintenance Letrozole versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Cancer Type: Unspecified

A Randomized, Double-Blind, Phase III Trial of Paclitaxel / Trastuzumab / Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

A Randomized, Phase II / III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin / Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin / Bevacizumab in Platinum Resistant Ovarian Cancer
Cancer Type: Ovarian Cancer

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy
Cancer Type: Unspecified

A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors
Cancer Type: Breast Cancer, Cervical Cancer, Lymphoma, Prostate Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Cancer Type: Unspecified

Cancer Moonshot Biobank Research Protocol
Cancer Type: Unspecified

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Cancer Type: Unspecified

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Cancer Type: Appendix Cancer, Bone and Soft Tissue (including Sarcoma), Brain Cancer , Colon/Rectal Cancer, Unknown Primary

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Cancer Type: Unspecified

EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
Cancer Type: Unspecified

EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Cancer Type: Unspecified

Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion Study to Alliance Study A011502
Cancer Type: Breast Cancer

Implementing a Virtual Tobacco Treatment in Community Oncology Practices: “Smoke Free Support Study 2.0”
Cancer Type: Unspecified

Improving Patient-Centered Communication in Breast Cancer: A RCT of a Shared Decision Engagement System (SHADES)
Cancer Type: Unspecified

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
Cancer Type: Unspecified

INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction / Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis
Cancer Type: Lung Cancer

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Cancer Type: Unspecified

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II / III Randomized Study of Chemoradiation versus Chemoradiation plus Atezolizumab
Cancer Type: Lung Cancer, Skin Cancer (Non-Melanoma)

Maintenance Chemotherapy versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Chemotherapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial
Cancer Type: Lung Cancer

MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Cancer Type: Unspecified

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Cancer Type: Unspecified

Older Non-Small Cell Lung Cancer Patients (> / = 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+ / - Chemotherapy (Oncologist’s / Patient’s Choice)
Cancer Type: Unspecified

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
Cancer Type: Unspecified

Phase II / III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Cancer Type: Unspecified

Phase II Randomized Trial of Avelumab plus Cetuximab versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Cancer Type: Unspecified

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Cancer Type: Prostate Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation
Cancer Type: Bladder Cancer

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
Cancer Type: Cervical Cancer

Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction
Cancer Type: Breast Cancer

Phase II-III Trial of Adjuvant Radiotherapy following Radical Prostatectomy with or without Adjuvant Docetaxel
Cancer Type: Prostate Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Cancer Type: Breast Cancer, Unknown Primary

Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Cancer Type: Unspecified

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Cancer Type: Unspecified

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
Cancer Type: Breast Cancer

Randomized Phase II / III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Cancer Type: Unspecified

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Cancer Type: Lymphoma

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Cancer Type: Melanoma

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Cancer Type: Lung Cancer

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
Cancer Type: Oral Cancer

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Unspecified

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Cancer Type: Unspecified

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Cancer Type: Breast Cancer

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases.
Cancer Type: Brain Cancer , Breast Cancer

The National Myelodysplastic Syndromes (MDS) Study
Cancer Type: Myelodysplastic Syndromes (MDS)

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Cancer Type: Unspecified

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a state-supported nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education to improve cancer care for Georgians in rural, urban, and suburban communities across the state.